Objective To evaluate protective effectiveness of 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13) on community-acquired pneumonia (CAP) among young children in Suzhou city.
Methods A retrospective cohort study was carried out among 59 927 children aged 0 − 18 months and having outpatient visit or hospitalization at Children's Hospital of Soochow University (SCH) from December 1, 2017 to June 30, 2019. The participants' information on outpatient visit or hospitalization were collected from the information system of SCH and that on PCV13 vaccination were extracted from the Immunization Information System of Suzhou Municipal Center for Disease Control and Prevention. Cox proportional hazard model was used to estimate the vaccine effectiveness (VE) of different doses of PCV13.
Results Of all the children followed-up, 12.4% (n = 7 459) were vaccinated with PCV13. Among the children having at least one dose, two doses, and three doses of PCV13 vaccination, the VE of PCV13 against CAP diagnosed at first outpatient visit or hospitalization during the follow-up period were 10.1% (95% confidence interval 95% CI: 3.3% − 18.1%), 15.7% (95% CI: 7.6% − 23.1%), and 20.3% (95% CI: 11.5% − 28.3%); while, the VE of PCV13 against CAP diagnosed during the whole follow-up period were 13.1% (95% CI: 6.0% − 20.0%), 17.5% (95% CI: 10.0% − 24.5%), and 22.2% (95% CI: 14.0% − 30.0%), respectively.
Conclusion PCV13 is of protective effectiveness against CAP in young children and the PCV13 vaccination of 3 doses is the most effective.
DownLoad: